NCT02738931 - Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

Dolutegravir 50 mg tablet

A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.

DRUG

Lamivudine 300 mg tablet

"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."

DRUG

Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)

Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

DRUG

Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)

Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.

Trial Locations (1)

66211

GSK Investigational Site, Overland Park